CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287
CNS Pharmaceuticals (NASDAQ:CNSP) has released a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital. The segment focuses on Glioblastoma Multiforme (GBM) treatment landscape and the company's lead product candidate, TPI 287.
Dr. Dunbar, who specializes in brain and spine tumor patient care, discusses the potential of TPI 287 as a treatment for GBM and its possible applications for metastatic tumors. The virtual segment is now available for viewing online.
CNS Pharmaceuticals (NASDAQ:CNSP) ha pubblicato un segmento Virtual Investor KOL Connect con la partecipazione della Dott.ssa Erin Dunbar, medico fondatore del Brain Tumor Center e Direttore di Neuro-Oncologia presso il Piedmont Atlanta Hospital. Il segmento si concentra sul panorama terapeutico del Glioblastoma Multiforme (GBM) e sul principale candidato farmaco dell'azienda, TPI 287.
La Dott.ssa Dunbar, specializzata nella cura dei pazienti con tumori cerebrali e spinali, discute il potenziale di TPI 287 come trattamento per il GBM e le sue possibili applicazioni per tumori metastatici. Il segmento virtuale è ora disponibile per la visione online.
CNS Pharmaceuticals (NASDAQ:CNSP) ha lanzado un segmento Virtual Investor KOL Connect con la participación de la Dra. Erin Dunbar, médica fundadora del Brain Tumor Center y Directora de Neuro-Oncología en el Piedmont Atlanta Hospital. El segmento se centra en el panorama del tratamiento del Glioblastoma Multiforme (GBM) y en el principal candidato a producto de la compañía, TPI 287.
La Dra. Dunbar, especialista en el cuidado de pacientes con tumores cerebrales y de columna, habla sobre el potencial de TPI 287 como tratamiento para GBM y sus posibles aplicaciones en tumores metastásicos. El segmento virtual ya está disponible para su visualización en línea.
CNS Pharmaceuticals (NASDAQ:CNSP)는 Dr. Erin Dunbar가 참여한 Virtual Investor KOL Connect 세그먼트를 공개했습니다. Dr. Dunbar는 Piedmont Atlanta 병원의 뇌종양센터 설립 의사이자 신경종양학 디렉터입니다. 이 세그먼트는 교모세포종(GBM) 치료 현황과 회사의 주요 후보 약물인 TPI 287에 중점을 둡니다.
뇌 및 척추 종양 환자 치료를 전문으로 하는 Dr. Dunbar는 GBM 치료제로서 TPI 287의 가능성과 전이성 종양에 대한 잠재적 적용에 대해 논의합니다. 이 가상 세그먼트는 현재 온라인에서 시청할 수 있습니다.
CNS Pharmaceuticals (NASDAQ:CNSP) a publié un segment Virtual Investor KOL Connect mettant en vedette Dr Erin Dunbar, médecin fondateur du Brain Tumor Center et directrice de la neuro-oncologie à l'hôpital Piedmont Atlanta. Ce segment porte sur le paysage du traitement du Glioblastome Multiforme (GBM) et sur le principal candidat médicament de l'entreprise, TPI 287.
Dr Dunbar, spécialisée dans la prise en charge des patients atteints de tumeurs cérébrales et spinales, discute du potentiel de TPI 287 comme traitement du GBM et de ses applications possibles pour les tumeurs métastatiques. Le segment virtuel est désormais disponible en ligne.
CNS Pharmaceuticals (NASDAQ:CNSP) hat einen Virtual Investor KOL Connect Abschnitt veröffentlicht, in dem Dr. Erin Dunbar, Gründungsärztin des Brain Tumor Center und Direktorin für Neuro-Onkologie am Piedmont Atlanta Hospital, vorgestellt wird. Der Abschnitt konzentriert sich auf die Behandlungsmöglichkeiten des Glioblastoma Multiforme (GBM) und das führende Produktkandidaten des Unternehmens, TPI 287.
Dr. Dunbar, spezialisiert auf die Behandlung von Patienten mit Hirn- und Wirbelsäulentumoren, spricht über das Potenzial von TPI 287 als Therapie für GBM und mögliche Anwendungen bei metastasierenden Tumoren. Der virtuelle Abschnitt ist jetzt online verfügbar.
- None.
- None.
Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar
HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, a founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, who specializes in the comprehensive care of brain and spine tumor patients who are battling both primary and metastatic tumors.
As part of the segment, Dr. Dunbar discussed the patient journey and current treatment landscape for Glioblastoma Multiforme and CNS Pharma's lead product candidate, TPI 287, and its potential as a treatment for GBM as well as for future indications in metastatic tumors.
The Virtual Investor KOL Connect segment featuring CNS Pharma is now available here.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the focus of CNS Pharmaceuticals' (CNSP) Virtual Investor KOL Connect segment?
Who is Dr. Erin Dunbar and what is her role in CNS Pharmaceuticals' presentation?
What potential applications are being discussed for CNS Pharmaceuticals' TPI 287?
Where can investors access CNS Pharmaceuticals' (CNSP) KOL Connect segment?
